Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W C Gruber

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Vaccine|August 9, 2012
A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trialP C Richmond, M D Nissen, H S Marshall, et al.
The Journal of Infectious Diseases|June 1, 1996
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators GroupW C Gruber, R B Belshe, J C King, et al.
Vaccine|May 31, 2011
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 yearsT F Schwarz, J Flamaing, H C Rümke, et al.
Vaccine|January 1, 1993
Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young childrenP A Piedra, W P Glezen, I Mbawuike, et al.
The New England Journal of Medicine|May 15, 1998
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in childrenR B Belshe, P M Mendelman, J Treanor, et al.
The Journal of Infectious Diseases|November 17, 1998
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F proteinR Malley, J DeVincenzo, O Ramilo, et al.
Vaccine|September 13, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccineK A Bryant, R Frenck, A Gurtman, et al.
The Pediatric Infectious Disease Journal|January 22, 2000
Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretionsR Malley, L Vernacchio, J Devincenzo, et al.
Pediatrics|March 1, 1997
Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study GroupW J Rodriguez, W C Gruber, R C Welliver, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 1, 2014
Predicting pneumococcal community-acquired pneumonia in the emergency department: evaluation of clinical parametersS M Huijts, W G Boersma, D E Grobbee, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Vaccine|August 9, 2012
A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trialP C Richmond, M D Nissen, H S Marshall, et al.
The Journal of Infectious Diseases|June 1, 1996
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators GroupW C Gruber, R B Belshe, J C King, et al.
Vaccine|May 31, 2011
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 yearsT F Schwarz, J Flamaing, H C Rümke, et al.
Vaccine|January 1, 1993
Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young childrenP A Piedra, W P Glezen, I Mbawuike, et al.
The New England Journal of Medicine|May 15, 1998
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in childrenR B Belshe, P M Mendelman, J Treanor, et al.
The Journal of Infectious Diseases|November 17, 1998
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F proteinR Malley, J DeVincenzo, O Ramilo, et al.
Vaccine|September 13, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccineK A Bryant, R Frenck, A Gurtman, et al.
The Pediatric Infectious Disease Journal|January 22, 2000
Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretionsR Malley, L Vernacchio, J Devincenzo, et al.
Pediatrics|March 1, 1997
Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study GroupW J Rodriguez, W C Gruber, R C Welliver, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 1, 2014
Predicting pneumococcal community-acquired pneumonia in the emergency department: evaluation of clinical parametersS M Huijts, W G Boersma, D E Grobbee, et al.
Pageof 4